BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Caterpillar’s revenue surges 24% to $20.5 billion as volume and pricing both accelerate, lifting margins to 20.9%

Moe Alsumidaie by Moe Alsumidaie
September 24, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Caterpillar reported second-quarter 2026 sales and revenues of $20.5 billion, a 24% increase from $16.6 billion in the same quarter last year, driven by $3.1 billion in higher sales volume and $595 million in favorable price realization. Operating profit margin expanded to 20.9% from 17.3% year-over-year, while adjusted operating margin reached 21.9% from 17.6%. The company generated its first-ever single-quarter revenue exceeding $20 billion, signaling sustained demand across all three primary segments.

The $3.974 billion revenue increase breaks down to $3.1 billion from higher sales volume, primarily equipment sales to end users, and $595 million from price realization. Construction Industries led segment growth at 35%, followed by Resource Industries at 20% and Power & Energy at 17%. Geographically, North America accelerated fastest at 37% growth, while Asia/Pacific grew only 4%. Profit per share reached $7.77 compared with $4.62 in the prior year quarter; adjusted profit per share was $8.17 versus $4.72. The company deployed $2.2 billion in the quarter for share repurchases ($1.5 billion) and dividends ($0.7 billion), while operating cash flow totaled $4.4 billion and enterprise cash stood at $6.7 billion. The document provides no forward guidance for future quarters or full-year 2026 results.

What it means

The 24% revenue growth substantially outpaces Caterpillar’s full-year 2025 growth rate of 4.3%, indicating a material acceleration in underlying demand rather than a seasonal or one-time event. The composition of the gain matters: volume growth of $3.1 billion reflects genuine end-user equipment purchases, not inventory building or channel stuffing, while $595 million in price realization shows the company is capturing pricing power without demand destruction. The fact that all three segments grew and all four geographic regions expanded (North America most sharply) suggests the strength is broad-based rather than concentrated in a single market or product line.

Year-by-year revenue growth shows Q2 2026 as a sharp break from Caterpillar’s recent trend, with volume and pricing both contributing to the jump. Interactive: hover for values. Official data via SEC EDGAR.

Operating margin expansion to 20.9% from 17.3% year-over-year, and adjusted margin to 21.9% from 17.6%, indicates that volume and pricing gains are flowing through to profit at a rate faster than revenue growth alone would predict. This suggests either favorable product mix (higher-margin equipment), manufacturing leverage as fixed costs spread across higher output, or both. The 16.5% operating margin reported for full-year 2025 sits well below the 20.9% achieved in this quarter, raising the question of whether Q2 2026 represents a cyclical peak or a sustained step up in profitability.

BullScope TerminalYou just read CATERPILLAR INC’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The open question the document leaves unresolved is whether this momentum persists or represents a pull-forward of demand. The company cites “strong order rates and a growing backlog” but provides no quantified backlog figures, forward guidance, or commentary on demand visibility beyond the current quarter. The absence of any forward statement, no raised, cut, or affirmed guidance, means the market has no official signal from management about whether the company expects this growth rate to continue, decelerate, or accelerate in the second half of 2026.

What to watch

The next material disclosure will be Caterpillar’s third-quarter 2026 earnings release, expected in late October or early November 2026, which will reveal whether the 24% revenue growth and 20.9% operating margin represent a sustained new operating level or a cyclical peak. Interim signals will come from any investor conference calls, machinery order data, or backlog commentary the company provides in earnings calls or investor presentations before then.

Source: the company’s 8-K filed 2026-08-04 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Caterpillar: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Caterpillar.

BullScope TerminalYou just read CATERPILLAR INC’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Procter & Gamble accelerates organic sales growth to 4% as pricing and volume both contribute

by Moe Alsumidaie
October 23, 2026
0

Procter & Gamble's first quarter of fiscal 2027 delivered organic sales growth of 4 percent, up from the prior year's 3.3 percent, driven b

Read moreDetails

Abbott to split Nutrition into independent company with $8.5 billion in sales by end of 2027

by Moe Alsumidaie
October 22, 2026
0

Abbott announced plans to separate its Nutrition business into a standalone publicly traded company by the end of 2027, creating a $8.5 bil

Read moreDetails

GE Aerospace raises 2026 guidance as commercial services orders surge 58 percent

by Moe Alsumidaie
October 21, 2026
0

GE Aerospace lifted full-year profit and cash flow targets after third-quarter orders jumped 58 percent, driven by a backlog of over $170 b

Read moreDetails

Biohaven licenses Japan and Asia rights to Graves’ disease candidate for $80 million upfront and 20% royalties

by Moe Alsumidaie
October 19, 2026
0

Biohaven has licensed its lead extracellular IgG degrader, BHV-1300, to Ono Pharmaceutical for exclusive development and commercialization

Read moreDetails

UnitedHealth’s operating margin surges as medical cost discipline offsets revenue decline

by Moe Alsumidaie
October 15, 2026
0

UnitedHealth Group raised full-year earnings guidance to at least $20.50 per share after third-quarter operating earnings jumped 53 percent

Read moreDetails
Next Post

Hill or Cliff? The One Exchange That Defines Merck Right Now

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Organon: The Company Earning More Per Sale Than Its Stock Suggests, With a Cloud Still Overhead

September 2, 2026

PepsiCo’s organic growth accelerates to 3.1% as international volume offsets North America pricing pressure

October 9, 2026

Trulieve: A $403 Million Loss That Isn’t What It Looks Like, and a Profit That Might Be

September 11, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.